Candidate: Vaccine candidate for COVID-19
Type: DNA plasmid vaccine designed to generate the SARS-CoV2 protein, which would become an antigen, and help people develop immunity against the virus.
Status: Cytiva (formerly part of GE Healthcare Life Sciences) said May 21 it was partnering with Takara Bio on a DNA vaccine candidate for COVID-19. Takara is working on the plasmid vaccine in collaboration with its designer, Prof. Ryuichi Morishita, MD, PhD, of Osaka University, and AnGes. The partners reason that plasmid DNA can be bio-manufactured in large quantities relatively quickly, allowing nimble ramp up of production.
COVID-19: 200 Candidates and Counting
To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:
● FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.
● DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data
● KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.
● TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.
GEN has also tagged the most common treatment types: